Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Imagine a company who has complete immunity for killing people!! 110% great investment!! Of course until the people make you accountable, then the games begin!!
Anyways hopefully you fuckin retards got a placebo and not the real deal clot shot$. And good luck to you all, but rest assured this O- specimen doesn’t need luck, I’ll put my blood on the pedestal to save any unvaccinated life. Unless a child needs me, that’s my only exception! But the rest of you fuckin retards can pound sand!!
Moderna (MRNA) Q1 2024 Earnings Call Transcript " Money Machine "
https://www.fool.com/earnings/call-transcripts/2024/05/02/moderna-mrna-q1-2024-earnings-call-transcript/
PFE/MRNA—1Q24 COVID-vaccine worldwide_market_share—>68/32 in favor of PFE.
https://www.accesswire.com/858697/moderna-reports-first-quarter-2024-financial-results-and-provides-business-updates
PFE’s 2024 guidance for Comirnaty sales is $5.0B (#msg-174337807); MRNA has not issued 2024 guidance for Spikevax, but rather for total corporate revenue including the not-yet-approved RSV vaccine.
Plenty of room to run from here
Today, we reported financial results and provided business updates for the first quarter of 2024.
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion
Initiated three new clinical studies evaluating Moderna's investigational individualized neoantigen therapy in combination with Merck's Keytruda® for treatment of patients with bladder cancer, kidney cancer and cutaneous squamous cell carcinoma
Advanced three new vaccine programs (Epstein-Barr virus, Varicella-Zoster virus, norovirus) toward Phase 3 clinical trials as announced at Vaccines Day investor event
RSV: The Company anticipates initial regulatory approvals of its RSV vaccine (mRNA-1345) beginning in the first half of 2024.
Moderna is targeting fall 2024 for its U.S. RSV vaccine launch, which will build upon the success of its commercial efforts in the fall COVID-19 market. The Company is encouraged by early indications of widespread consumer awareness and established demand in the RSV market, which Moderna will enter with a strong competitive profile with robust clinical efficacy data, a well-established safety and tolerability profile for its mRNA technology, and as the only pre-filled syringe (PFS) product available.
The PFS ready-to-use formulation will save pharmacists and clinicians time, potentially alleviating wait times and reducing the burden on pharmacy staff. In a study funded by Moderna, the PFS presentation was three to four times more efficient than vaccines requiring reconstitution, measured in doses per hour and based on mean time of preparation.
Cash and Investments: Year-end cash and investments for 2024 are projected to be approximately $9 billion.
Moderna Puts Up Big Quarterly Beat; Could Shares Notch A Breakout
https://www.investors.com/news/technology/moderna-stock-moderna-earnings-q1-2024/?src=A00220
https://news.modernatx.com/news/news-details/2024/Moderna-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Updates/default.aspx
Moderna (MRNA) earns a Zacks Rank #3 two days from its next quarterly earnings release on May 2, 2024, and its Most Accurate Estimate comes in at -$3.55 a share.
By taking the percentage difference between the -$3.55 Most Accurate Estimate and the -$3.59 Zacks Consensus Estimate, Moderna has an Earnings ESP of 0.99%.
Does it actually matter
Are there any voices
To the contrayer
contrary
the Company will present data from its respiratory portfolio, including vaccines and vaccine candidates against COVID-19 (mRNA-1273, mRNA-1283), influenza (mRNA-1010, mRNA-1011/1012), and respiratory syncytial virus (RSV) (mRNA-1345), along with data related to its latent virus portfolio regarding cytomegalovirus (CMV), at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Barcelona, Spain, from April 27-30, 2024.
https://investors.modernatx.com/news/news-details/2024/Moderna-To-Present-Respiratory--Cytomegalovirus-Research-at-the-ESCMID-Global-Congress/default.aspx
British patients test world’s first personalised mRNA jab for melanoma
Moderna and MSD are researching how their therapy could treat a wide range of cancers.
https://www.independent.co.uk/news/health/moderna-british-patients-bray-fat-duck-b2535073.html
Should You Buy Moderna Before May 12?
Though GSK and Pfizer both got a head start in this market, Moderna could carve out market share and eventually take a leadership position for two reasons. First, mRNA-1345 is the only one to come in a pre-filled syringe format. This makes it easier and faster for healthcare providers to administer, and results in fewer errors. All of this is a big plus for those giving the vaccine and those receiving it.
Second, in the phase 3 clinical trial of mRNA-1345, Moderna didn't observe cases of Guillain-Barre syndrome, a rare neurological disorder. But GSK and Pfizer both reported cases of this autoimmune condition in their trials. Some doctors, seeing this data, may recommend the Moderna product to their patients over others.
https://www.fool.com/investing/2024/04/26/should-you-buy-moderna-before-may-12/
Moderna CEO says AI will help scientists understand ‘most diseases’ in 3 to 5 years
https://gizmodo.com/moderna-ceo-chatgpt-employees-vaccines-openai-1851435620
Moderna and OpenAI Collaborate To Advance mRNA Medicine
At Moderna, OpenAI’s GPTs Are Changing Almost Everything
https://investors.modernatx.com/news/news-details/2024/Moderna-and-OpenAI-Collaborate-To-Advance-mRNA-Medicine/default.aspx
Now that's safe and effective
~~~ Along with informed consent ~~~
(2:28)
SM-102
Smoke&Mirrors
Nothing but crickets
It did break the blood brain barrior
How does one know this
This vaccine could drive growth for years if it gets approved:
Merck and Moderna split the costs and profits of the mRNA-4157 program equally, because both contributed their technology and intellectual property to the effort. In fact, it's Merck's best-selling immuno-oncology drug Keytruda that's a key component of most of the personalized cancer vaccine formulations being tested currently. Whereas mRNA-4157 aims to activate the immune system against a tumor, Keytruda protects the cells of the immune system from being hampered by some of the defenses that tumor cells often have.
So good results in the clinic for Moderna are also good results for Merck, and it looks like the pair are cooking up some more bullish results for the future too.
https://finance.yahoo.com/news/1-green-flag-moderna-merck-124500083.html
in the brain-----
Fighting over death patents
While genocide
Plays its role
US_district_court pauses MRNA’s patent-infringement suit vs PFE/BNTX pending USPTO input:
https://www.reuters.com/legal/litigation/pfizer-wins-pause-modernas-covid-19-patent-lawsuit-2024-04-12/
In the veins
What is the difference between
Life
And understanding
Whiskey$$$$$$
What was behind them
To which
It propagated
What is in those vaccines
Towards that future
HUGE$ head and neck squamous cell carcinoma (HNSCC). Data from the study showed that treatment with the combination not only achieved positive clinical responses in HPV- HNSCC patients but even showed evidence of activation of immune responses. The combined therapy was also found to be safe and well-tolerated by study participants.
Per management, treatment with the combination achieved an objective response rate (ORR) in six out of 22 patients, including two complete responses and four partial ones. The disease control rate was 63.6%. These results were presented at the American Society of Cataract and Refractive Surgery (ASCRS) earlier this week.
Not only was the combination found to be safe, researchers found evidence that it activated immune responses
https://s29.q4cdn.com/435878511/files/doc_presentations/2024/Apr/08/12091203_aacr2024_bauman_poster_159-76x94-76_v22_final-61.pdf
vaccine shows benefit in head and neck cancer in early study
Data from 22 patients who received the vaccine, mRNA-4157, in combination with Keytruda was reported at the American Association for Cancer Research Annual Meeting at San Diego on Monday.
The vaccine combination showed evidence of activation of immune responses in patients, and was found to be safe and well tolerated in the study, Moderna said.
We can see that institutions own the lion's share in the company with 68% ownership
next catalyst -The PDUFA (Prescription Drug User Fee Act) action date for mRNA-1345 is May 12, 2024
Cancer vaccines----- towards a new future
https://www.nature.com/collections/dfajababaj
I load if 30 comes....They have trial results on herpes coming out June 2025
Bird flu pandemic could be ‘100 times worse’ than COVID, scientists warn
Around 52% of humans who have contracted H5N1 since 2003 have died, according to the World Health Organization.
https://cdn.who.int/media/docs/default-source/wpro---documents/emergency/surveillance/avian-influenza/ai_20240329.pdf
https://nypost.com/2024/04/04/us-news/bird-flu-pandemic-could-be-100-times-worse-than-covid-scientists-warn/
Childhood decease is caused
~~~ By the 72 injections before age 18~~~
(1:14)
Watch the FULL interview on CHD TV: https://live.childrenshealthdefense.org/chd-tv/events/
Info that matters
mRNA drug offers hope for treating a devastating childhood disease
Nassrine Fawaz in Livonia, Michigan, has witnessed a transformation in her 4-year-old daughter, who has received mRNA-3927 for the past 2.5 years. After each infusion, “she’s focused, she’s energetic, she’s up and ready for the day — all of those great things”.
https://www.nature.com/articles/d41586-024-00954-4
A wave would make
For a good reply
When surfing
In a tsunami
a judge just came down with a partial decision in Arbutus favor not a ruling, just a decision that strengthens their hand against Moderna
"He ruled in favor of Roivant subsidiary Arbutus on 3 of 4 patent claims...It is our understanding Moderna can't appeal for now since this isn't a formal 'judgment' but rather a 'decision'", Jefferies analysts wrote in a note.
A trial in the case is currently set to begin next April.....
Reuters!
Nature is being turned on its head
To make it something
That it is not
Long Live Pussy$$$$$$$$$$
What is one trying to say
In one's own words
Toothpicks
Are a far better remedy
Cancer-busting vaccines
Treatments that could train the immune system to identify and destroy cancer cells are on the way.
https://www.nature.com/articles/d41586-024-00842-x
MIT spinout Strand Therapeutics has developed a new class of mRNA molecules that can sense where they are in the body, for more targeted and powerful treatments.
https://news.mit.edu/2024/strand-therapeutics-unlocks-mrna-cancer-fighting-potential-0327
many as 15 new products over the coming five years- If Moderna even achieves a small part of that goal, investors could be looking at a new era of revenue growth for the company!
Followers
|
176
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
13328
|
Created
|
12/10/18
|
Type
|
Free
|
Moderators DewDiligence Vexari axelvento |
2021 was a year of monumental impact and change for Moderna
Moderna entered 2021 with a strong cash position of approximately $5.25 billion. We have used this capital to invest in R&D and scale our development pipeline and manufacturing capabilities to maximize our impact on human health.
As we close our books for 2021, the company’s cash, cash equivalents and investments as of December 31, 2021, were more than $17 billion. We now have the resources to scale our investments and do even more to positively impact human health with mRNA medicines. This is just the beginning.
.
https://www.modernatx.com/newsroom/our-blog-coding-region/moderna-2021-shareholder-letter
Moderna is entering 2022 with a remarkable team poised to continue advancing mRNA vaccines and therapeutics into new areas for patients. We have a clear and exciting strategic path to do so, and a strong cash position.
Priority two is to go after the most important latent viruses and develop first-in-class vaccines against them. We want to protect our fellow human beings from suffering from the long-term damage caused by these viruses. Too many people have the quality of their health impacted because decades before, they were infected with a latent virus. We envision a world where vaccines against all the most important latent viruses are available to all.
Priority three is to bring to market therapeutics based on mRNA-encoded proteins, like our current pipeline in oncology, cardiology, rare genetic diseases and autoimmune diseases.
Priority four is to bring to market innovative therapeutics based on mRNA-encoded gene editing enzymes.
Moderna expects to enroll approximately 34,000 participants in multiple countries
RSV is a leading cause of severe respiratory illness in older adults (65+) and young children; there is no approved vaccine to prevent RSV
RSV illness in older adults results in an estimated $3 billion in annual medical costs in the U.S. each year
NOVEMBER, 18, 2021
https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-First-Participant-Dosed-in-Phase-2-3-Study-of-its-mRNA-Respiratory-Syncytial-Virus-RSV-Vaccine/default.aspx
MODERNA ANNOUNCES POSITIVE DATA FROM PHASE 2 STUDY OF MRNA VEGF-A THERAPEUTIC IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING SURGERY
Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose
SPIKEVAX has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
807 million doses of Moderna's COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries
https://investors.modernatx.com/news/news-details/2022/Moderna-Receives-Full-U.S.-FDA-Approval-for-COVID-19-Vaccine-Spikevax/default.aspx
Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29
Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29
Moderna increased its 2022 signed advance purchase agreements to approximately $19 billion, with additional signed options of approximately $3 billion; numerous discussions ongoing with governments for the fall of 2022 and 2023
Moderna received full U.S. FDA approval for COVID-19 vaccine, Spikevax
Moderna announces new bivalent booster candidate (mRNA-1273.214) combining Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273)
Company now has 44 programs in development
Moderna announces a new $3 billion share repurchase plan
https://investors.modernatx.com/news/news-details/2022/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2021-Financial-Results-and-Provides-Business-Updates/default.aspx
Facility to manufacture drug substance with opportunity for fill/finish and packaging capabilities
Moderna investing up to $500 million to produce up to 500 million doses each year for the African continent
Moderna will invest in building mRNA capabilities in Africa
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Memorandum-of-Understanding-with-the-Government-of-the-Republic-of-Kenya-to-Establish-its-First-mRNA-Manufacturing-Facility-in-Africa/default.aspx
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |